Activation of orexin-A receptors in the periaqueductal gray increases pain tolerance in healthy and diabetic male rats

Document Type : Original Research

Authors
T. Shirafkan 1
M. Sharifi 2
A. Komaki 3
A. Sarihi 3
1 Department of Biology, Faculty of Basic Sciences, Islamic Azad University of Hamadan, Iran
2 Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
3 Department of Neuroscience, School of Sciences and Advanced Technology in Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract
Introduction: Diabetic neuropathic pain is a common complication of diabetes. While previous research has shown that direct administration of the neuropeptide orexin-A into the brain can elicit analgesic effects, the specific central nervous system regions and mechanisms mediating these pain-relieving actions remain incompletely characterized.

Methods: The current study used male Wistar rats to investigate the antinociceptive effects of administering orexin-A directly into the ventrolateral periaqueductal gray (vlPAG) region of the midbrain, assessed via the tail-flick test performed 5 minutes post-injection. The experiments compared the effects of intra-vlPAG orexin-A administration in both healthy control and diabetic animal models.

Results: In the control groups, the analgesic effects of intra-vlPAG orexin-A were found to be sustained over the 1-hour observation period. Importantly, orexin-A elicited a rapid and potent analgesic response in the diabetic animal groups as well.

Conclusion: Collectively, these findings suggest a key functional role for the vlPAG orexinergic system in modulating pain tolerance, with implications for the potential therapeutic targeting of this system in the management of debilitating neuropathic pain conditions like diabetic peripheral neuropathy.

Keywords

Subjects

[1] Obrosova IG. Update on the pathogenesis of diabetic neuropathy. Current diabetes reports. 2003;3(6):439-45.
[2] Roa-Coria JE, Pineda-Farias JB, Barragán-Iglesias P, Quiñonez-Bastidas GN, Zúñiga-Romero Á, Huerta-Cruz JC, et al. Possible involvement of peripheral TRP channels in the hydrogen sulfide-induced hyperalgesia in diabetic rats. BMC neuroscience. 2019;20:1-17.
[3] Can ÖD, Öztürk Y, Öztürk N, Sagratini G, Ricciutelli M, Vittori S, et al. Effects of treatment with St. John's Wort on blood glucose levels and pain perceptions of streptozotocin-diabetic rats. Fitoterapia. 2011;82(4):576-84.
[4] Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in endocrinology. 2013;4:18.
[5] Peyron C, Tighe DK, Van Den Pol AN, De Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. Journal of Neuroscience. 1998;18(23):9996-10015.
[6] Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain research. 1999;827(1-2):243-60.
[7] van den Pol AN. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. Journal of Neuroscience. 1999;19(8):3171-82.
[8] Yamamoto T, Nozaki‐Taguchi N, Chiba T. Analgesic effect of intrathecally administered orexin‐A in the rat formalin test and in the rat hot plate test. British journal of pharmacology. 2002;137(2):170-6.
[9] Bingham S, Davey P, Babbs A, Irving E, Sammons M, Wyles M, et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain. 2001;92(1-2):81-90.
[10] Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proceedings of the National Academy of Sciences. 1999;96(19):10911-6.
[11] Ho Y-C, Lee H-J, Tung L-W, Liao Y-Y, Fu S-Y, Teng S-F, et al. Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. Journal of Neuroscience. 2011;31(41):14600-10.
[12] Paxinos G, Watson C. The rat brain in stereotaxic coordinates: hard cover edition: Elsevier; 2006.
[13] de Lecea L, Kilduff T, Peyron C, Gao X-B, Foye P, Danielson P, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences. 1998;95(1):322-7.
[14] Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-85.
[15] Behbehani MM, Park MR, Clement ME. Interactions between the lateral hypothalamus and the periaqueductal gray. Journal of Neuroscience. 1988;8(8):2780-7.
[16] Horvath TL, Peyron C, Diano S, Ivanov A, Aston‐Jones G, Kilduff TS, et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. Journal of Comparative Neurology. 1999;415(2):145-59.
[17] Tao R, Ma Z, McKenna J, Thakkar M, Winston S, Strecker R, et al. Differential effect of orexins (hypocretins) on serotonin release in the dorsal and median raphe nuclei of freely behaving rats. Neuroscience. 2006;141(3):1101-5.
[18] Toyama S, Shimoyama N, Shimoyama M. The analgesic effect of orexin-A in a murine model of chemotherapy-induced neuropathic pain. Neuropeptides. 2017;61:95-100.
[19] Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, Kato M, et al. Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and-2) in mice. Peptides. 2005;26(5):767-77.
[20] Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation. Biomedicine & Pharmacotherapy. 2017;90:187-93.
[21] Esmaeili M-H, Reisi Z, Ezzatpanah S, Haghparast A. Functional interaction between orexin‐1 and CB 1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats. European journal of pain. 2016;20(10):1753-62.
[22] Zarmehri HA, Semnanian S, Fathollahi Y, Erami E, Khakpay R, Azizi H, et al. Intra-periaqueductal gray matter microinjection of orexin-A decreases formalin-induced nociceptive behaviors in adult male rats. The journal of pain. 2011;12(2):280-7.
[23] Niknia S, Kaeidi A, Hajizadeh MR, Mirzaei MR, Khoshdel A, Hajializadeh Z, et al. Neuroprotective and antihyperalgesic effects of orexin-A in rats with painful diabetic neuropathy. Neuropeptides. 2019;73:34-40.
[24] Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20.
[25] Vincent AM, Mclean LL, Backus C, Feldman EL. Short‐term hyperglycemia produces oxidative damage and apoptosis in neurons. The FASEB Journal. 2005;19(6):1-24.
[26] Esmaeili-Mahani S, Vazifekhah S, Pasban-Aliabadi H, Abbasnejad M, Sheibani V. Protective effect of orexin-A on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. Neurochemistry International. 2013;63(8):719-25.
Pathobiology Reserach
Volume 25, Issue 4
October 2022
Pages 59-65